IP Library › Granted Patent US 11,091,495
Granted Patent B2
US 11,091,495 · App. 17/116,270 · Granted Aug 17, 2021

Substituted imidazo[1,2-c]pyrimidines as PRC2 inhibitors

Inventors: Matthew Arnold Marx (San Diego, CA); Matthew Randolph Lee (Del Mar, CA); Thomas P. Bobinski (San Diego, CA); Aaron Craig Burns (San Diego, CA); Nidhi Arora (San Diego, CA); James Gail Christensen (San Diego, CA); John Michael Ketcham (San Diego, CA)
Assignee: MIRATI THERAPEUTICS, INC.
C07D487/04
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,091,495
App. No.
17/116,270
Granted
Aug 17, 2021
Kind
B2
Abstract

The present invention relates to compounds that inhibit Polycomb Repressive Complex 2 (PRC2) activity. In particular, the present invention relates to compounds, pharmaceutical compositions and methods of use, such as methods of treating cancer using the compounds of Formula (I) and pharmaceutical compositions of the present invention.

Claims (39)

1. A compound selected from the group consisting of:

a pharmaceutically acceptable salt thereof.

2. The compound according to claim 1 , wherein the compound is:

or a pharmaceutically acceptable salt thereof.

3. The compound according to claim 1 , wherein the compound is:

or a pharmaceutically acceptable salt thereof.

4. The compound according to claim 1 , wherein the compound is:

or a pharmaceutically acceptable salt thereof.

5. The compound according to claim 1 , wherein the compound is:

or a pharmaceutically acceptable salt thereof.

6. The compound according to claim 1 , wherein the compound is:

or a pharmaceutically acceptable salt thereof.

7. The compound according to claim 1 , wherein the compound is:

or a pharmaceutically acceptable salt thereof.

8. The compound according to claim 1 , wherein the compound is:

or a pharmaceutically acceptable salt thereof.

9. The compound according to claim 1 , wherein the compound is:

or a pharmaceutically acceptable salt thereof.

10. The compound according to claim 1 , wherein the compound is:

or a pharmaceutically acceptable salt thereof.

11. The compound according to claim 1 , wherein the compound is:

or a pharmaceutically acceptable salt thereof.

12. The compound according to claim 1 , wherein the compound is:

or a pharmaceutically acceptable salt thereof.

13. The compound according to claim 1 , wherein the compound is:

or a pharmaceutically acceptable salt thereof.

14. A pharmaceutical composition comprising a pharmaceutically acceptable excipient and a therapeutically effective amount of a compound according to claim 1 , or a pharmaceutically acceptable salt thereof.

15. A pharmaceutical composition comprising a pharmaceutically acceptable excipient and a therapeutically effective amount of a compound according to claim 2 , or a pharmaceutically acceptable salt thereof.

16. A pharmaceutical composition comprising a pharmaceutically acceptable excipient and a therapeutically effective amount of a compound according to claim 3 , or a pharmaceutically acceptable salt thereof.

17. A pharmaceutical composition comprising a pharmaceutically acceptable excipient and a therapeutically effective amount of a compound according to claim 4 , or a pharmaceutically acceptable salt thereof.

18. A pharmaceutical composition comprising a pharmaceutically acceptable excipient and a therapeutically effective amount of a compound according to claim 5 , or a pharmaceutically acceptable salt thereof.

19. A pharmaceutical composition comprising a pharmaceutically acceptable excipient and a therapeutically effective amount of a compound according to claim 6 , or a pharmaceutically acceptable salt thereof.

20. A pharmaceutical composition comprising a pharmaceutically acceptable excipient and a therapeutically effective amount of a compound according to claim 7 , or a pharmaceutically acceptable salt thereof.

21. A pharmaceutical composition comprising a pharmaceutically acceptable excipient and a therapeutically effective amount of a compound according to claim 8 , or a pharmaceutically acceptable salt thereof.

22. A pharmaceutical composition comprising a pharmaceutically acceptable excipient and a therapeutically effective amount of a compound according to claim 9 , or a pharmaceutically acceptable salt thereof.

23. A pharmaceutical composition comprising a pharmaceutically acceptable excipient and a therapeutically effective amount of a compound according to claim 10 , or a pharmaceutically acceptable salt thereof.

24. A pharmaceutical composition comprising a pharmaceutically acceptable excipient and a therapeutically effective amount of a compound according to claim 11 , or a pharmaceutically acceptable salt thereof.

25. A pharmaceutical composition comprising a pharmaceutically acceptable excipient and a therapeutically effective amount of a compound according to claim 12 , or a pharmaceutically acceptable salt thereof.

26. A pharmaceutical composition comprising a pharmaceutically acceptable excipient and a therapeutically effective amount of a compound according to claim 13 , or a pharmaceutically acceptable salt thereof.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 15, 2021
From: MARX, MATTHEW ARNOLD; LEE, MATTHEW RANDOLPH; BOBINSKI, THOMAS P.; BURNS, AARON CRAIG; ARORA, NIDHI; CHRISTENSEN, JAMES GAIL; KETCHAM, JOHN MICHAEL
To: MIRATI THERAPEUTICS, INC.
Reel/Frame 054938/0796 →
Continuity (5)
Continuation 16966708
Provisional Application 62624176 · Jan 31, 2018
Provisional Application 62672701 · May 17, 2018
Provisional Application 62747736 · Oct 19, 2018
Related Publication 20210101904A1 · Apr 8, 2021
Cited By (3)
US 12,252,493 US 12,371,435 US 12,421,228